MedTrace Logo

Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial

NCT02867891 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 396

Last updated 2017-01-18

No results posted yet for this study

Summary

In this trial the investigators will evaluate the outcomes of 4 pre-defined groups of individuals according to the therapeutic intervention. The investigators will determine the outcome of each group by monitoring the survival and the response rates of patients with FLT3-ITD AML relapse after allo-HSCT.

Conditions

Sponsors & Collaborators

  • Robert Zeiser

    lead OTHER

Principal Investigators

  • Robert Zeiser, Prof. Dr. · Medical Center University of Freiburg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-03-31
Primary Completion
2016-12-31
Completion
2016-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02867891 on ClinicalTrials.gov